A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris

Autor:	Kragballe, Knud, Austad, J, Barnes, L, Bibby, A, de la Brassinne, M, Cambazard, F, Flemming, C, Heikkilä, H, Jolliffe, D, Peyri, J, Svensson, Å, Toole, J, Wozel, G
Jazyk:	angličtina
Rok vydání:	2006
Zdroj:	Kragballe, K, Austad, J, Barnes, L, Bibby, A, de la Brassinne, M, Cambazard, F, Flemming, C, Heikkilä, H, Jolliffe, D, Peyri, J, Svensson, Å, Toole, J & Wozel, G 2006, ' A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet ® /Daivobet ® /Taclonex ® ) in the treatment of psoriasis vulgaris ', Br. J. Dermatol., no. 154, pp. 1155-1160 .
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pure_au_____::721a55b66b3e25ae7eb26da6ffc3dc61 https://pure.au.dk/portal/da/publications/a-52week-randomized-safety-study-of-a-calcipotriolbetamethasone-dipropionate-twocompound-product-dovobetdaivobettaclonex-in-the-treatment-of-psoriasis-vulgaris(93241d50-4fa4-11db-bee9-02004c4f4f50).html Zobrazit plný text záznamu